BioCryst Pharmaceuticals, Inc. (BCRX) vs Eton Pharmaceuticals, Inc. (ETON)
BioCryst Pharmaceuticals, Inc. and Eton Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. BioCryst Pharmaceuticals, Inc. is the larger, with a market value of $2.2B against $1.7B — 1.3× the size. BioCryst Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Eton Pharmaceuticals, Inc. trades at 123×. Eton Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 81.5% against 68.7%. Eton Pharmaceuticals, Inc. has the higher net margin (12.0% vs −40.9%) and the higher return on invested capital (21.4% vs −610.6%). Across the 17 metrics below, BioCryst Pharmaceuticals, Inc. leads on 10 and Eton Pharmaceuticals, Inc. on 7.
Valuation
Profitability
| Metric | BCRX | ETON | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.78% | 57.87% | 53.94% |
| Operating margin | (33.29%) | 15.44% | 0.00% |
| Net margin | (40.90%) | 12.02% | 0.00% |
| Free cash flow margin | 39.75% | (7.94%) | 0.00% |
| Return on equity | 87.84% | 35.97% | (0.40%) |
| Return on assets | (75.79%) | 11.67% | (3.32%) |
| Return on invested capital | (610.55%) | 21.39% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack